[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100432253":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":44,"centralContacts":49,"locations":56,"responsibleParty":101,"collaborators":104,"id":108,"slug":109,"hasResults":110,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":54,"eligibilityCriteria":114,"healthyVolunteers":110,"sex":115,"minAge":54,"maxAge":116,"enrollmentInfo":117,"targetDuration":54,"studyType":120,"phases":121,"briefSummary":123,"conditions":124,"keywords":54,"overallStatus":59,"whyStopped":54,"lastUpdateSubmitDate":126,"lastUpdatePostDateStruct":127,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":135},{"fullName":5,"class":6},"Emory University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Diagnostic (sMRI)","EXPERIMENTAL","Patients undergo sMRI over less than 1 hour within 7 days prior to start of standard of care radiation therapy and at 10 weeks.",[13,14],"Procedure: Magnetic Resonance Spectroscopic Imaging","Device: Proton Therapy",{"label":16,"type":17,"description":18,"interventionNames":19},"Group 2","ACTIVE_COMPARATOR","Patients will undergo 3-4 sMRI scans at baseline prior to RT, 1 month, 4 months, and 7 months after RT, and\u002For at any time of suspected tumor recurrence.",[13,14],[21,34],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"PROCEDURE","Magnetic Resonance Spectroscopic Imaging","Undergo sMRI",[9,16],[27,28,29,30,31,32,33],"1H- Nuclear Magnetic Resonance Spectroscopic Imaging","1H-nuclear magnetic resonance spectroscopic imaging","Magnetic Resonance Spectroscopy","MRS","MRS Imaging","MRSI","Proton Magnetic Resonance Spectroscopic Imaging",{"type":35,"name":36,"description":37,"armGroupLabels":38,"otherNames":39},"DEVICE","Proton Therapy","Target volume treatment",[9,16],[40,41,42,29,43],"Spectroscopic MRI","Proton Radiation Therapy","sMRI imaging","3D whole brain MR spectroscopic imaging sequence",[45],{"name":46,"affiliation":47,"role":48},"Bree R Eaton, MD","Emory University Hospital\u002FWinship Cancer Institute","PRINCIPAL_INVESTIGATOR",[50],{"name":51,"role":52,"phone":53,"phoneExt":54,"email":55},"Bree Eaton, MD","CONTACT","404-778-3473",null,"brupper@emory.edu",[57,78,92],{"facility":58,"status":59,"city":60,"state":61,"zip":62,"country":63,"countryCode":64,"cosmosGeoPoint":65,"geoPoint":70,"contacts":71},"Emory Proton Therapy Center","RECRUITING","Atlanta","Georgia","30308","United States","US",{"type":66,"coordinates":67},"Point",[68,69],-84.38798,33.749,{"lat":69,"lon":68},[72,76],{"name":73,"role":52,"phone":74,"phoneExt":54,"email":75},"Ardith R. DeShay","404-251-0753","adeshay@emory.edu",{"name":77,"role":48,"phone":54,"phoneExt":54,"email":54},"Bree R. Eaton, MD",{"facility":79,"status":80,"city":60,"state":61,"zip":81,"country":63,"countryCode":64,"cosmosGeoPoint":82,"geoPoint":84,"contacts":85},"Children's Healthcare of Atlanta - Scottish Rite","NOT_YET_RECRUITING","30322",{"type":66,"coordinates":83},[68,69],{"lat":69,"lon":68},[86,90],{"name":87,"role":52,"phone":88,"phoneExt":54,"email":89},"Christina Lomba","404-785-4803","christina.lomba@choa.org",{"name":91,"role":48,"phone":54,"phoneExt":54,"email":54},"Bree R. Eaton",{"facility":47,"status":59,"city":60,"state":61,"zip":81,"country":63,"countryCode":64,"cosmosGeoPoint":93,"geoPoint":95,"contacts":96},{"type":66,"coordinates":94},[68,69],{"lat":69,"lon":68},[97,100],{"name":98,"role":52,"phone":54,"phoneExt":54,"email":99},"Hillary Gaines","hillary.gaines@emoryhealthcare.org",{"name":77,"role":48,"phone":54,"phoneExt":54,"email":54},{"type":48,"investigatorFullName":102,"investigatorTitle":103,"investigatorAffiliation":5,"oldNameTitle":54,"oldOrganization":54},"Bree Eaton","Principal Investigator",[105],{"name":106,"class":107},"National Cancer Institute (NCI)","NIH","100432253","spectroscopic-mri-guided-proton-therapy-in-assessing-metabolic-change-in-pediatric-patients-with-brain-tumors-100432253",false,"NCT04908709","Spectroscopic MRI Guided Proton Therapy in Assessing Metabolic Change in Pediatric Patients With Brain Tumors","Spectroscopic MRI Guided Proton Therapy for Pediatric High-Grade Glioma (RAD4500)","Inclusion Criteria:\n\n* Pathologically diagnosed high-grade glioma (World Health Organization \\[WHO\\] grade 3-4). Patients with a radiographically diagnosed high-grade glioma may enroll prior to pathologic confirmation, but would be removed from study if pathology did not confirm the diagnosis of high-grade glioma.\n* Primary tumor located within the supratentorial brain.\n* Recommended to receive definitive radiation therapy.\n* Able to receive MRI scans.\n* Both males and females, and members of all races and ethnic groups are eligible for this trial.\n\nExclusion Criteria:\n\n* Patients with pacemakers, non-titanium aneurysm clips, neurostimulators, cochlear implants, non-titanium metal in ocular structures, or other incompatible implants which makes MRI safety an issue are excluded.\n* Patients that have any significant medical illnesses that in the investigator's opinion cannot be adequately tolerate MRI scan are excluded.\n* Pathology demonstrated low-grade glioma or other benign or non-invasive brain tumor.","ALL","21 Years",{"count":118,"type":119},25,"ESTIMATED","INTERVENTIONAL",[122],"NA","This trial studies how well spectroscopic magnetic resonance imaging (MRI) guided proton therapy works in assessing metabolic change in pediatric patients with brain tumors. The non-invasive imaging, such as spectroscopic MRI may help to map the differences in tumor metabolism compared to healthy tissue without injection of any contrast agent.",[125],"Malignant Brain Glioma","2026-03-02",{"date":128,"type":129},"2026-03-04","ACTUAL",{"date":131,"type":129},"2018-12-20",{"date":133,"type":119},"2030-10-13",{"name":5,"class":6},3]